Redensyl for Androgenetic Alopecia
Verdict: Taiwan Regulatory Restriction
Across 2 PubMed studies, the evidence for Redensyl in Androgenetic Alopecia grades Tier C — weak evidence.
C 🟠 C Weak Evidence Taiwan Regulatory Restriction
Why this grade7-layer evidence engine
⚖️
Scoring transparency
All scores computed by a 7-layer evidence engine — fully auditableRaw score 0.43
D
C
B
A
S
← counter-evidence / ineffectiveeffective / strong evidence →
Final grade
C · Taiwan Regulatory Restriction
Confidence
90%
Highly consistent evidence
Evidence level
E6
Multiple smaller RCTs (n<500)
▸View the full decision path (audit trail)
- compute_raw_score — 加權公式: L2×0.30 + L3×0.25 + L5×0.25 + L11×0.10 + L1×0.10 = 0.427
- tier_from_score — 依分數區間映射至 tier letter
- apply_hec_rules — 無高階證據可裁決
- tier_strict_requirement_check — Tier 條件達標，未降階
- detect_disputes — 偵測到 0 個 hard + 1 個 soft dispute
- decide_status — 依 tier + dispute 結果決定 status
PubMed studies (2)L2 · primary research & systematic reviews
A randomized, single-blinded, vehicle-controlled study of a topical active blend in the treatment of androgenetic alopecia
Finding: Among patients on the active Redensyl+Sepicontrol lotion, the majority showed moderate improvement (reported as roughly great 7.7% / moderate 73.1% / stable 19.2% in active group), with the active arm outperforming vehicle. NOTE: this is a Redensyl-CONTAINING multi-ingredient blend (also Sepicontrol A5), single-blinded, with small n; it does NOT isolate Redensyl monotherapy effect.
View on PubMed A Comparative Study of Topical Procapil With Platelet-Rich Plasma Therapy Versus Topical Redensyl, Saw Palmetto, and Biotin With Platelet-Rich Plasma Therapy in the Treatment of Androgenetic Alopecia
Finding: AGA grading score differed significantly between groups (P<0.05); authors concluded PRP with adjuvant Redensyl + saw palmetto + biotin can be a better alternative to current PRP therapies. NOTE: Redensyl was combined with saw palmetto, biotin AND platelet-rich plasma — no vehicle/placebo arm and no isolation of Redensyl's individual contribution.
View on PubMed